Idiopathic Pulmonary Fibrosis Serum proteomic analysis before and after nintedanib therapy

Idiopathic pulmonary fibrosis (IPF) is a fatal progressive disease with a median survival of 2–5 years. Nintedanib is a small tyrosine kinase inhibitor that reduces IPF progression, significantly slowing the annual decline in Forced Vital Capacity (FVC). Very little data is available on the molecula...

Descripción completa

Detalles Bibliográficos
Autores principales: Landi, Claudia, Bergantini, Laura, Cameli, Paolo, d’Alessandro, Miriana, Carleo, Alfonso, Shaba, Enxhi, Rottoli, Paola, Bini, Luca, Bargagli, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7287088/
https://www.ncbi.nlm.nih.gov/pubmed/32523095
http://dx.doi.org/10.1038/s41598-020-66296-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7287088/
https://www.ncbi.nlm.nih.gov/pubmed/32523095
http://dx.doi.org/10.1038/s41598-020-66296-z

Ejemplares similares